Literature DB >> 1615583

Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon-alpha.

P Rajala1, E Kaasinen, E Rintala, K Jauhiainen, M Nurmi, O Alfthan, M Lähde.   

Abstract

The cytostatic activity of five Bacillus Calmette-Guérin (BCG) strains (Pasteur, Evans, Tice, RIVM and Connaught) on human transitional cell cancer T24 cells was examined. A striking effect was noted even in 2-day cultures, and the effect was more pronounced when the cells were incubated for 5 days with different BCG strains alone. The concentrations needed were about the same as those used in clinical practice (10(9) colony-forming units of Pasteur strain in 100 ml buffered saline solution). Combination with mitomycin C or interferon-alpha-2b potentiated the cytostatic effect. A slight difference in cytostatic activity between different BCG strains was found.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615583     DOI: 10.1007/bf00299720

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  5 in total

1.  Intravesical cytostatics: pH-dependence of antitumour activity.

Authors:  K Jauhiainen; L Kangas; H Käpylä; O Alfthan
Journal:  Urol Res       Date:  1985

2.  Selecting initial therapy for bladder cancer.

Authors:  M S Soloway
Journal:  Cancer       Date:  1987-08-01       Impact factor: 6.860

3.  Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

Authors:  A Morales; D Eidinger; A W Bruce
Journal:  J Urol       Date:  1976-08       Impact factor: 7.450

4.  Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro.

Authors:  L Kangas; M Grönroos; A L Nieminen
Journal:  Med Biol       Date:  1984

5.  Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer.

Authors:  A Morales
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450

  5 in total
  9 in total

1.  Enhanced antitumor effect of combination intravesical mitomycin C and bacillus Calmette-Guerin therapy in an orthotopic bladder cancer model.

Authors:  Masashi Matsushima; Minoru Horinaga; Ryuichi Fukuyama; Hitoshi Yanaihara; Eiji Kikuchi; Makoto Kawachi; Masahiro Iida; Yoko Nakahira; Mototsugu Oya; Hirotaka Asakura
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

2.  Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay.

Authors:  Sarah Schott; Markus Wallwiener; Beate Kootz; Harald Seeger; Tanja Fehm; Hans Neubauer
Journal:  Invest New Drugs       Date:  2011-05-21       Impact factor: 3.850

3.  ATP chemosensitivity testing of new antitumor duplex drugs linking 3`-C-ethynylycytidine (ECyd) and 2´-deoxy-5-fluorouridine (5-FdU) in comparison to standard cytostatica and combinations thereof.

Authors:  Sarah Schott; Markus Wallwiener; Beate Kootz; Harald Seeger; Tanja Fehm; Hans Neubauer
Journal:  Invest New Drugs       Date:  2009-12-09       Impact factor: 3.850

Review 4.  Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder. The Finnbladder Research Group.

Authors:  O Alfthan; K Jauhiainen; E Kaasinen; T Liukkonen
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 5.  Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.

Authors:  Homayoun Zargar; Jonathan Aning; Joseph Ischia; Alan So; Peter Black
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

6.  Sequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trial.

Authors:  Robert S Svatek; Xiang Ru Zhao; Edwin E Morales; Mithilesh K Jha; Timothy Y Tseng; Cory M Hugen; Vincent Hurez; Javier Hernandez; Tyler J Curiel
Journal:  Clin Cancer Res       Date:  2014-11-25       Impact factor: 12.531

7.  BCG strain S4-Jena: An early BCG strain is capable to reduce the proliferation of bladder cancer cells by induction of apoptosis.

Authors:  Katja Schwarzer; Martin Foerster; Thomas Steiner; Inge-Marie Hermann; Eberhard Straube
Journal:  Cancer Cell Int       Date:  2010-06-29       Impact factor: 5.722

8.  Cytokine-mediated antitumor effect of bacillus Calmette-Guérin on tumor cells in vitro.

Authors:  H Kurisu; H Matsuyama; Y Ohmoto; T Shimabukuro; K Naito
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

9.  Induction of tumor-specific CD8+ cytotoxic T lymphocytes from naïve human T cells by using Mycobacterium-derived mycolic acid and lipoarabinomannan-stimulated dendritic cells.

Authors:  Yuji Tomita; Eri Watanabe; Masumi Shimizu; Yasuyuki Negishi; Yukihiro Kondo; Hidemi Takahashi
Journal:  Cancer Immunol Immunother       Date:  2019-09-17       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.